Latest information on COVID-19

Stanford Amyloid Center

The Stanford Amyloid Center comprises a comprehensive team of physicians, scientists, nurses, and counselors dedicated to improving the care of patients with amyloidosis.

Since its founding in 2008, the Stanford Amyloid Center has grown into one of the largest treatment centers for amyloidosis in the world and the largest in the western United States.  We focus on comprehensive, multidisciplinary patient care, patient education, and research— both in basic discovery research and in clinical trials. Our team spans many divisions and multiple departments at Stanford and is led by Dr. Ronald Witteles (Cardiovascular Medicine), Dr. Michaela Liedtke (Hematology), and Dr. Ronglih Liao (discovery science).

We invite you to explore this website to learn more about the disease and about our program at the Stanford Amyloid Center.

Featured News

AL amyloidosis survival 'markedly improved' with current treatments

Changes in the landscape of effective therapies for systemic light chain (AL) amyloidosis have led to substantial survival improvements at all stages of the disease, a study led by Dr. Witteles and the Stanford Amyloid Center